- 2020. Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017. Substance Abuse Treatment, Prevention, and Policy.
- 2020. Potentially addictive drugs dispensing to patients receiving opioid agonist therapy: a register-based prospective cohort study in Norway and Sweden from 2015 to 2017. BMJ Open. 10 sider.
- 2020. On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: A prospective cohort study from 2013 to 2017. BMJ Open. 1-9.
- 2020. Living a normal life? Follow-up study of women who had been in opioid maintenance treatment during pregnancy. Journal of Substance Abuse Treatment.
- 2020. Impact of clinical and sociodemographic factors on fatigue among patients with substance use disorder: a cohort study from Norway for the period 2016–2020. Substance Abuse Treatment, Prevention, and Policy. 11 sider.
- 2020. Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; A prospective cohort study in Norway from 2013 to 2017. BMC Health Services Research. 1-12.
- 2020. Dispensation of attention deficit hyperactivity disorder (ADHD) medications in patients receiving opioid agonist therapy; A national prospective cohort study in Norway from 2015 to 2017. BMC Psychiatry. 1-12.
- 2019. Methadone serum concentrations and influencing factors: A naturalistic observational study. Psychopharmacology. 3159-3167.
- 2019. Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV). BMC Infectious Diseases. 1-9.
- 2017. Combined Effect of CYP2B6 Genotype and Other Candidate Genes on a Steady-State Serum Concentration of Methadone in Opioid Maintenance Treatment. Therapeutic Drug Monitoring. 550-555.
- 2011. Clinical characteristics of patients with drug hypersensitivity in Norway: a single-centre study. Pharmacoepidemiology and Drug Safety. 506-513.
Brev til redaktøren
- 2013. Westin og medarbeidere svarer (om pregabalinmisbruk). Tidsskrift for Den norske legeforening. 1045-1045.
- 2010. Hypersensitivity Reactions to Drugs: A Retrospective Analysis of Clinical Characteristics of Patients Consulting for Suspected Drug Hypersensitivity in an Allergy Center in Norway.
- 2019. Integrated care of severe infectious diseases to people with substance use disorders; a systematic review. BMC Infectious Diseases. 1-15.
- 2013. Pregabalin bør flyttes til reseptgruppe B 615. Tidsskrift for Den norske legeforening. 615-616.